Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InflaRx NVMEX:IFRXN 35 Days Payable is 0.00 as of Jun. 2026. GuruFocus rates MEX:IFRXN with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 704 Biotechnology companies, InflaRx NV ranks better than 74.43% on this metric.
The historical data trend for InflaRx NV's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IFRXN vs VRXA, TTRX, IRD: Days Payable Comparison
For the Biotechnology subindustry, InflaRx NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InflaRx NV Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InflaRx NV's Days Payable distribution charts can be found below:
* The bar in red indicates where InflaRx NV's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
InflaRx NV's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InflaRx NV (MEX:IFRXN) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InflaRx NV and its competitors. Over the past decade, InflaRx NV's Days Payable has ranged from 391.49 to 5,771.41. According to the industry distribution chart, InflaRx NV ranks #180 out of 704 companies in the Biotechnology industry, placing it in the top 25.6%.
Is InflaRx NV's Days Payable too high?
InflaRx NV's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 391.49 to a high of 5,771.41. Based on the distribution chart, InflaRx NV ranks #180 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, InflaRx NV has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Days Payable compare to VRXA and TTRX?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #180 out of 704 companies for Days Payable. This puts InflaRx NV in the upper half of its industry. The industry median Days Payable is 112.72. Historically, InflaRx NV's own Days Payable has ranged from 391.49 to 5,771.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InflaRx NV and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InflaRx NV's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (MEX:IFRXN) has a current Days Payable of 0.00. The current Days Payable is 0.00. InflaRx NV's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For InflaRx NV (MEX:IFRXN), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
35GF Score
Get the complete analysis for MEX:IFRXN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IFRXN has been successfully added to your 
